Prospera Insights
Back to queue

Bandhan Healthcare Fund

Bandhan Mutual Fund · 153972 · Quant Rank #333

Structural GatesFully Researched (Deep)Prospera Research Confidence: LOW
ANALYST_REVIEWED

Research Confidence reflects source quality and evidence depth — it is independent of the score below. A fund can score highly with low confidence, or moderately with high confidence.

Real Evidence
CategoryPH
AUM₹319 Cr
Benchmark—
RiskometerVery High
TERInsufficient data
InceptionInsufficient data
Track RecordInsufficient data
Fund ManagerViraj Kulkarni and Brijesh Shah
AUM Floor₹300 Cr
Min Track3 yrs
Max Alloc12%
Returns vs Benchmark
WindowFundBenchmark
Calculated Parameters
FMTInsufficient data — no real 'managing since' date collected for this scheme's current manager
AMQ5/10
AUTInsufficient data — no real 3-months-ago AUM evidence (AMFI's live feed only carries current + ~1-month-ago; needs a genuine dated snapshot from an earlier sync)
ERSInsufficient data — no TER evidence collected for this scheme
Structural Gates
Gate 1 — EligibilityUNKNOWN

AUM floor: PASS · Track record: UNKNOWN · SEBI: UNKNOWN

Gate 2 — Quant ScreenFAIL
Gate 3 — Top 10FAIL
Gate 4 — Top 5FAIL
Gate 5 — Top 2 ICFAIL
Candidate's 22.7 would rank #3 among 2 real existing category scores (top 2 = recommendable).
Analyst Name
MOM — Momentum
7% weight
Deep Research

3–6M price+flow vs benchmark · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:50:36 AM

CON — Consistency
10% weight
Deep Research

3Y/5Y quartile rank stability · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:50:36 AM

PQT — Portfolio Quality
11% weight
Deep ResearchConfidence: MEDIUM

PE, concentration, churn · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:50:36 AM

FMQ — Fund Mgr Quality
12% weight
Deep ResearchConfidence: LOW

Philosophy, communication, style drift · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:50:36 AM

VAL — Valuation Risk
10% weight
Deep Research

Portfolio PE/PB vs category avg · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:50:36 AM

STW — Sector Tailwinds
9% weight
Deep ResearchConfidence: LOW

Policy/macro drivers 12-18M · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:50:36 AM

DSP — Downside Protection
8% weight
Deep Research

Max DD, Sortino, bear markets · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:50:36 AM

OPP — Outperformance Prob.
8% weight
Deep ResearchConfidence: LOW

Analyst 12M alpha probability · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:50:36 AM

THS — Thesis Strength
2% weight
Deep ResearchConfidence: LOW

Analyst 12-24M thesis conviction · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:50:36 AM

V6 Final Score
22.7
/ 100 — Final Score
AVOID
MOM
0.0
CON
0.0
PQT
5.5
FMQ
4.8
VAL
0.0
STW
5.4
DSP
0.0
OPP
3.2
FMT
—
AMQ
3.0
AUT
—
ERS
—
THS
0.8
Data-limited: FMT, AUT, ERS (insufficient data — never defaulted to 0)
Source Evidence (6)
Fund ManagerViraj Kulkarni and Brijesh Shah
Value Research Online — public fund page (Regular Plan; Direct Plan holdings/manager identical, TER differs) as of 2026-08-27
Value Research RatingUnrated
Value Research Online — public fund page as of 2026-08-27
Top 5 HoldingsSun Pharmaceutical 10.91%, Apollo Hospitals 8.41%, Cipla 6.92%, Torrent Pharma 4.50%, Divi's Lab 4.04% (top-5 total 34.78%)
Value Research Online — public fund page as of 2026-08-27
AUM (Cr.)319
Value Research Online — public fund page as of 2026-08-27
Riskometer (Scheme)Very High
Value Research Online — public fund page as of 2026-08-27
AMC Total AUM (Lakh Cr.)2.04
AMFI quarterly AAUM disclosure (Apr–Jun 2026), via RightAdvise aggregation of official AMFI figures as of 2026-06-30
Audit Log
MOM ∅ → 0 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:50:36 AM
“[DEEP RESEARCH] No real return-vs-benchmark figure collected; fund launched November 2025, too young. Scored 0 (N/A).”
CON ∅ → 0 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:50:36 AM
“[DEEP RESEARCH] Confirmed UNRATED by Value Research directly on its own fund page (launched Nov 2025). Scored 0 (N/A).”
PQT ∅ → 5 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:50:36 AM
“[DEEP RESEARCH] Real top-5 holdings: Sun Pharmaceutical 10.91%, Apollo Hospitals 8.41%, Cipla 6.92%, Torrent Pharma 4.50%, Divi's Lab 4.04% (top-5 total 34.78%) — reputable large pharma/hospital names, moderate concentration.”
FMQ ∅ → 4 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:50:36 AM
“[DEEP RESEARCH] Real managers: Viraj Kulkarni and Brijesh Shah, managing since the fund's own November 2025 launch — under 1 year, no independent track record yet.”
VAL ∅ → 0 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:50:36 AM
“[DEEP RESEARCH] No PE/PB evidence found. Scored 0 (N/A).”
STW ∅ → 6 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:50:36 AM
“[DEEP RESEARCH] Real, current sector-level tailwind in Indian pharma/healthcare, though not independently verified for this specific fund's own relative performance.”
DSP ∅ → 0 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:50:36 AM
“[DEEP RESEARCH] No real drawdown evidence found; fund too young. Scored 0 (N/A).”
OPP ∅ → 4 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:50:36 AM
“[DEEP RESEARCH, analyst judgment] Very young, unrated fund with no independent track record — insufficient real evidence for more than a cautious view.”
THS ∅ → 4 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:50:36 AM
“[DEEP RESEARCH] Standard concentrated pharma-sector mandate, real but unremarkable relative to peers on the evidence found.”